NCT06583837

Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma

A Prospective, Multicenter, Phase II Study of Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of Local-stage Mucosa Associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Investigate the efficacy and safety of Orelabrutinib followed by response-adapted ultra-low dose 4Gy radiation in the treatment of local-stage MALT lymphoma

Detailed description

This prospective, multicenter trial is trying to evaluate the efficacy and safety of Orelabrutinib followed by response-adapted ultra-low dose 4Gy radiation as first-line treatment of local-stage mucosa associated lymphoid tissue extranodal marginal zone lymphoma

Conditions

• Lymphoma, B-Cell, Marginal Zone

Interventions

Type	Name	Description
DRUG	Orelabrutinib	Orelabrutinib was administrated for 12 weeks
RADIATION	response-adapted radiation	response-adapted ultra-low dose 4Gy radiation

Timeline

• Start date: 2024-09-10
• Primary completion: 2025-08-18
• Completion: 2027-09-01
• First posted: 2024-09-04
• Last updated: 2026-02-27

Locations

1 site across 1 country: China